Recent evidence indicates that PGC-1α activation exerts neuroprotective effects by suppressing neuroinflammation in animal models of Parkinson’s disease, depression, and brain injury (Corona and Duchen 2015; Fu et al., 2020; Han et al., 2021). Here, PPARGC1A is linked to Parkinson disease.